A guide for the diagnosis of rare and undiagnosed disease: beyond the exome
Руководство по диагностике редких и недиагностированных заболеваний: за пределами экзома
2022-02-27
SCID: 54.1/mbbdm2sj
Discuss with AI
long-read sequencingmulti-omics profilingphenotype matchingundiagnosed rare diseaseswhole-genome sequencing
Figures from the paper
Abstract (AI)
Rare diseases affect 30 million people in the USA and more than 300-400 million worldwide, often causing chronic illness, disability, and premature death. Traditional diagnostic techniques rely heavily on heuristic approaches, coupling clinical experience from prior rare disease presentations with the medical literature. A large number of rare disease patients remain undiagnosed for years and many even die without an accurate diagnosis. In recent years, gene panels, microarrays, and exome sequencing have helped to identify the molecular cause of such rare and undiagnosed diseases. These technologies have allowed diagnoses for a sizable proportion (25-35%) of undiagnosed patients, often with actionable findings. However, a large proportion of these patients remain undiagnosed. In this review, we focus on technologies that can be adopted if exome sequencing is unrevealing. We discuss the benefits of sequencing the whole genome and the additional benefit that may be offered by long-read technology, pan-genome reference, transcriptomics, metabolomics, proteomics, and methyl profiling. We highlight computational methods to help identify regionally distant patients with similar phenotypes or similar genetic mutations. Finally, we describe approaches to automate and accelerate genomic analysis. The strategies discussed here are intended to serve as a guide for clinicians and researchers in the next steps when encountering patients with non-diagnostic exomes.
Key Findings
1
A substantial proportion of rare-disease patients remains undiagnosed after exome sequencing, requiring diagnostic strategies beyond exome analysis.
2
Automated and accelerated genomic-analysis approaches are needed to improve the efficiency of evaluating patients with non-diagnostic exomes.
3
Computational methods can identify geographically distant patients with similar phenotypes or genetic mutations, supporting rare-disease diagnosis.
4
Gene panels, microarrays, and exome sequencing identify molecular diagnoses in approximately 25–35% of previously undiagnosed patients, often yielding actionable findings.
5
Whole-genome sequencing and complementary long-read, pan-genome, transcriptomic, metabolomic, proteomic, and methylation technologies may reveal diagnoses missed by exome sequencing.
Research Object
rare and undiagnosed disease patients with non-diagnostic exomes
Research Subject
post-exome diagnostic strategies and technologies for identifying the molecular causes of disease
Publication Details
Publication Date
2022-02-27
Journal
Publisher
ISSN
Cited by
393
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai10
Initial sequencing and analysis of the human genome2001
A global reference for human genetic variation2015
Analysis of protein-coding genetic variation in 60,706 humans2016
The mutational constraint spectrum quantified from variation in 141,456 humans2020
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells2013
Genetic effects on gene expression across human tissues2017
OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders2014
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis2005
Finding missed cases of familial hypercholesterolemia in health systems using machine learning2019
The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems2021